指南与共识淋巴瘤

第十届国际华氏巨球蛋白血症工作组共识治疗推荐

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.
指南 / 共识 · Lancet Haematol · 2020-01-01

第十届国际华氏巨球蛋白血症工作组(IWWM)基于专家共识更新了治疗方案推荐。对于有症状患者,一线首选含利妥昔单抗的烷化剂或蛋白酶体抑制剂方案,以及BTK抑制剂(单用或联合利妥昔单抗)。复发患者可再用原方案或其他一线方案,新型BTK抑制剂和维奈克拉是新兴选择。治疗选择应结合患者临床特征、基因组学和药物可及性。

要点

  • 有症状患者一线首选:利妥昔单抗联合烷化剂或蛋白酶体抑制剂,或BTK抑制剂(单用/联合利妥昔单抗)。
  • 复发患者若初始缓解持久,可再用原方案或其他一线方案。
  • 新型BTK抑制剂和维奈克拉安全有效,为新兴治疗选择。

核心结论

  • 更新了华氏巨球蛋白血症的治疗推荐,强调基于临床特征、基因组学和药物可及性个体化选择方案。

研究设计与样本

  • 国际共识专家组基于第十届IWWM会议(2018年纽约)及后续电话会议(2019年6月、2020年1月)制定,无外部资金支持。

主要发现

  • 烷化剂(苯达莫司汀、环磷酰胺)和蛋白酶体抑制剂(硼替佐米、卡非佐米、伊沙佐米)联合利妥昔单抗,以及BTK抑制剂(伊布替尼)单用或联合利妥昔单抗,为有症状患者首选一线方案。
  • 复发患者若初始缓解持久,可再用原方案或其他一线方案。
  • 新型BTK抑制剂(阿卡替尼、泽布替尼、tirabrutinib)和BCL2拮抗剂维奈克拉安全有效,为新兴选择。

临床怎么用

  • 根据患者临床特征、基因组学特征和药物可及性选择治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Waldenström macroglobulinaemia is an indolent B-cell lymphoma with clearly defined criteria for diagnosis, initiation of therapy, and response, which was established by consensus panels at previous International Workshops for Waldenström Macroglobulinaemia (IWWM). The treatment options for Waldenström macroglobulinaemia continued to be researched after the publication of the eighth IWWM consensus recommendations in 2016, and at the tenth IWWM in New York, USA (October, 2018) an international consensus panel was formed to update treatment recommendations. Participants were selected as members of the consensus panel based on their expertise on Waldenström macroglobulinaemia. The initial live discussion took place during the tenth IWWM meeting and two separate teleconferences were held in June, 2019, and January, 2020, to refine recommendations. No external or financial support was received for the elaboration of these recommendations. According to these updated consensus recommendations, alkylating drugs (bendamustine, cyclophosphamide) and proteasome inhibitors (bortezomib, carfilzomib, ixazomib), both in combination with rituximab, as well as BTK inhibitors (ibrutinib), alone or in combination with rituximab, are preferred first-line therapy options for symptomatic patients with Waldenström macroglobulinaemia. In previously treated patients with Waldenström macroglobulinaemia who had an initial durable response, reuse of a previous regimen or another primary therapy regimen are acceptable options. Novel BTK inhibitors (acalabrutinib, zanubrutinib, tirabrutinib) and the BCL2 antagonist venetoclax appear safe and active, and represent emerging options for the treatment of Waldenström macroglobulinaemia. The choice of therapy should be guided by the patient's clinical profile, genomic features, and drug availability.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020. PMID: 33091356. doi:10.1016/S2352-3026(20)30224-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。